Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Total Current Liabilities came in at $73.4 million in Q4 2025, up 20.9% YoY from $60.7 million in Q4 2024, and down 11.59% on a QoQ basis from $83.1 million in Q3 2025.
Autolus Therapeutics (AUTL) Total Current Liabilities (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Total Current Liabilities data on file, last reported at $73.4 million in Q4 2025.
- Quarterly Total Current Liabilities rose 20.9% year-over-year to $73.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.4 million (up 20.9% YoY) and the FY2025 annual result came in at $73.4 million, up 20.9% from the prior year.
- Total Current Liabilities declined to $73.4 million in Q4 2025, from $83.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $83.1 million in Q3 2025 to a low of $28.2 million in Q2 2021.
- A 5-year average of $46.2 million and a median of $41.0 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities declined 15.11% — and 2025, when it soared 66.61%.
- Tracing AUTL's Total Current Liabilities over 5 years: stood at $28.6 million in 2021, then surged by 62.4% to $46.4 million in 2022, then decreased by 3.51% to $44.7 million in 2023, then surged by 35.78% to $60.7 million in 2024, then rose by 20.9% to $73.4 million in 2025.
- The last three Total Current Liabilities figures came in at $73.4 million (Q4 2025), $83.1 million (Q3 2025), and $68.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | 68.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.79 Mn |
| Dec 31, 2025 | 73.44 Mn |
| Sep 30, 2025 | 83.07 Mn |
| Jun 30, 2025 | 68.15 Mn |
| Mar 31, 2025 | 66.62 Mn |
| Dec 31, 2024 | 60.74 Mn |
| Sep 30, 2024 | 52.47 Mn |
| Jun 30, 2024 | 40.90 Mn |
| Mar 31, 2024 | 43.99 Mn |
| Dec 31, 2023 | 44.74 Mn |
| Sep 30, 2023 | 37.54 Mn |
| Jun 30, 2023 | 41.06 Mn |
| Mar 31, 2023 | 39.64 Mn |
| Dec 31, 2022 | 46.37 Mn |
| Sep 30, 2022 | 38.82 Mn |
| Jun 30, 2022 | 35.52 Mn |
| Mar 31, 2022 | 28.84 Mn |
| Dec 31, 2021 | 28.55 Mn |
| Sep 30, 2021 | 34.56 Mn |
| Jun 30, 2021 | 28.19 Mn |